15:06 , Sep 1, 2017 |  BC Week In Review  |  Company News

Janssen gains MDD compound CERC-501 from Cerecor

Cerecor Inc. (NASDAQ:CERC) divested its CERC-501 to the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) for $25 million and up to $20 million in regulatory milestones. Janssen will assume responsibility for ongoing clinical...
01:39 , May 5, 2017 |  BC Week In Review  |  Clinical News

Cerecor reports Ph II depression data for CERC-501

Cerecor Inc. (NASDAQ:CERC) reported top-line data from a Phase II trial in 8 evaluable patients with treatment-resistant depression on stable antidepressant therapy showing that once-daily CERC-501 led to a "clinically meaningful" 2-point improvement compared to...
01:00 , Dec 21, 2016 |  BC Week In Review  |  Clinical News

CERC-501: Ph II data

Top-line data from a double-blind, 2-way crossover, U.S. Phase II trial in 71 heavy smokers who are not seeking treatment for tobacco use disorder showed that once-daily 15 mg CERC-501 for 8 days missed the...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

CERC-501: Completed Phase II enrollment

Cerecor completed enrollment of 71 heavy cigarette smokers who are not seeking treatment for tobacco use disorder in a double-blind, placebo-controlled, 2-way crossover, U.S. Phase II trial evaluating 15 mg oral CERC-501 once daily for...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

CERC-501: Phase II started

Cerecor said investigators began a double-blind, placebo-controlled, 2-way crossover, U.S. Phase II trial to evaluate 10 mg oral CERC-501 once daily for 8 days in about 20 heavy smokers undergoing overnight nicotine deprivation. NIH is...
02:24 , Oct 16, 2015 |  BC Extra  |  Financial News

Cerecor raises $26M in IPO

Cerecor Inc. (NASDAQ:CERCU) lost $0.10 to $6.40 in its first day of trading Thursday after it raised $26 million through the sale of 4 million units at $6.50 in an IPO underwritten by Maxim Group...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Company News

Eli Lilly, Cerecor deal

Eli Lilly granted Cerecor exclusive, worldwide rights to develop and commercialize CERC-501 . The kappa opioid receptor ( KOR ; OPRK1 ) antagonist has completed Phase I testing to treat depression and co-occurring substance use...
01:42 , Feb 21, 2015 |  BC Extra  |  Company News

Cerecor licenses KOR antagonist from Lilly

Eli Lilly and Co. (NYSE:LLY) granted Cerecor Inc. (Baltimore, Md.) exclusive, worldwide rights to LY2456302, a kappa opioid receptor ( KOR ) ( OPRK1 ) antagonist. Lilly previously developed the candidate to treat co-occurring substance...